HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Meiqi Song Selected Research

1-hydroxymethylpyrene

1/2021Potent aneugenicity of 1-methylpyrene in human cells dependent on metabolic activation by endogenous enzymes.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Meiqi Song Research Topics

Disease

5Hepatocellular Carcinoma (Hepatoma)
03/2022 - 01/2020
2Neoplasms (Cancer)
01/2022 - 02/2021
1Renal Cell Carcinoma (Grawitz Tumor)
01/2022
1Hypoxia (Hypoxemia)
01/2022
1Psoriasis (Pustulosis Palmaris et Plantaris)
09/2020

Drug/Important Bio-Agent (IBA)

3EnzymesIBA
01/2021 - 12/2020
2Ethanol (Ethyl Alcohol)IBA
03/2022 - 01/2020
2Cytochrome P-450 CYP2E1 (CYP2E1)IBA
03/2022 - 01/2020
1Cytochrome P-450 CYP3A InhibitorsIBA
03/2022
12,2',4,4'-tetrabromodiphenyl etherIBA
03/2022
14,4'-hexafluorisopropylidene diphenolIBA
03/2022
1Ketoconazole (Nizoral)FDA LinkGeneric
03/2022
1Rifampin (Rifampicin)FDA LinkGeneric
03/2022
1Cytochrome P-450 CYP3AIBA
03/2022
1Interferon-gamma (Interferon, gamma)IBA
01/2022
1Transforming Growth Factor beta (TGF-beta)IBA
01/2022
1Interferon-alpha (Interferon Alfa)IBA
01/2022
1IronIBA
01/2022
1Proteins (Proteins, Gene)FDA Link
01/2022
1Reactive Oxygen Species (Oxygen Radicals)IBA
01/2022
1Interleukin-6 (Interleukin 6)IBA
01/2022
1RNA (Ribonucleic Acid)IBA
01/2022
1Messenger RNA (mRNA)IBA
01/2022
1Constitutive Androstane ReceptorIBA
01/2021
11-hydroxymethylpyreneIBA
01/2021
1XenobioticsIBA
01/2021
1Aryl Hydrocarbon Receptors (Aryl Hydrocarbon Receptor)IBA
01/2021
1Pregnane X ReceptorIBA
01/2021
1Imiquimod (Aldara)FDA LinkGeneric
09/2020
12,3,3',4,4'-pentachlorobiphenylIBA
01/2020

Therapy/Procedure

1Immunotherapy
02/2021